Last reviewed · How we verify
Prednisone in full dose
Prednisone in full dose is a Small molecule drug developed by Zhi-Hong Liu, M.D.. It is currently in Phase 1 development.
Prednisone is a small molecule used in the treatment of various conditions, including kidney transplant, multiple sclerosis, IgA Nephropathy, Idiopathic Membranous Nephropathy, and melanoma stage III. It is typically used in conjunction with other treatments, such as abatacept, standard of care at US transplant centers, or plegridy, as part of a comprehensive treatment plan.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Prednisone in full dose |
|---|---|
| Sponsor | Zhi-Hong Liu, M.D. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation (PHASE2)
- Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) (PHASE1, PHASE2)
- A Study of Anti-CD38 Monoclonal Antibody (SG301) Subcutaneous Injection in Children With Nephrotic Syndrome With Frequent Relapses or Steroid Dependence (PHASE2)
- Upadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induction for Inpatients and Outpatients With Acute Severe Ulcerative Colitis (PHASE4)
- Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis (PHASE2)
- BDB-001 Phase III Trial in ANCA-Associated Vasculitis (PHASE3)
- Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma (PHASE3)
- Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prednisone in full dose CI brief — competitive landscape report
- Prednisone in full dose updates RSS · CI watch RSS
- Zhi-Hong Liu, M.D. portfolio CI
Frequently asked questions about Prednisone in full dose
What is Prednisone in full dose?
Who makes Prednisone in full dose?
What development phase is Prednisone in full dose in?
Related
- Manufacturer: Zhi-Hong Liu, M.D. — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing